The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation
The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation
复制标题
DOI：
10.1186/1471-2431-14-213
复制
发表时间：
2014-08-27
期刊：
影响因子：
2.4
通讯作者：
Davis, Peter G.
中科院分区：
文献类型：
--
作者：
Dargaville, Peter A.;Kamlin, Camille Omar F.;Davis, Peter G.
背景：现在公认，早产儿在年龄=0.45岁时=0.30，持续性呼吸暂停或持续性酸中毒)。主要结果是死亡或生理性支气管肺发育不良的综合结果，次要结果包括死亡率；主要新生儿发病率；所有呼吸支持和住院模式的持续时间；霍巴特方法的安全性；以及两年的结果。总共将有606名婴儿参加。这项试验将在全球30个中心进行，预计将于2017年底完成。讨论：微创表面活性物质疗法有可能减轻早产儿呼吸道疾病的负担。这项试验将提供确凿的证据，证明这种方法在护理孕25-28周出生的早产儿方面的有效性。
Background: It is now recognized that preterm infants = 0.30 at an age = 0.45, unremitting apnoea or persistent acidosis). Primary outcome is the composite of death or physiological bronchopulmonary dysplasia, with secondary outcomes including incidence of death; major neonatal morbidities; durations of all modes of respiratory support and hospitalisation; safety of the Hobart method; and outcome at 2 years. A total of 606 infants will be enrolled. The trial will be conducted in >30 centres worldwide, and is expected to be completed by end-2017.Discussion: Minimally-invasive surfactant therapy has the potential to ease the burden of respiratory morbidity in preterm infants. The trial will provide definitive evidence on the effectiveness of this approach in the care of preterm infants born at 25-28 weeks gestation.